Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
genetic diseases
Biotech
Merck KGaA pledges $50M to new biotech with eye to acquisition
The cash will power Saturnus Bio's research into genetic heart diseases, with Merck KGaA holding the exclusive right to buy the NewCo down the line.
Darren Incorvaia
Jun 23, 2026 10:16am
Sanofi, Wave post updates in race to end AATD’s 40-year drought
May 18, 2026 4:30pm
Genentech drug fails rare disease study, raising obesity questions
Mar 20, 2026 2:11pm
Alltrna CEO departs amid 35% layoff round
Mar 6, 2026 8:30pm
Atrium arises from Avidity buyout with $270M, preclinical assets
Feb 27, 2026 11:05am
Senate hearing takes aim at FDA's rare disease review process
Feb 26, 2026 3:50pm
